drugset / Trial / NCT00387023

Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma

NCT00387023

NaSingle-groupOpen-labelTreatment

Summary

Primary Objectives: 1. To evaluate the efficacy of Zevalin for the treatment of low-grade follicular Non-Hodgkin's lymphoma of the orbit or mucosa-associated lymphoid tissue (MALT) of conjunctiva using radiographic imaging, clinical examination (slit lamp biomicroscopy and external examination of the conjunctiva), and external photography whenever possible. 2. To establish the safety profile in this patient population using clinical examination including slit lamp biomicroscopy, and evaluation of the tear film with Schirmer's test. 3. To establish the dosimetry for Zevalin in the orbit in the first 3 patients who agree to undergo dosimetry.

Timeline

Start
2004-02
Primary completion
2012-07
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Rituximab Monoclonal antibody 250 mg/m2 Intravenous
Subject ibritumomab tiuxetan Monoclonal antibody 0.3 unknown Intravenous
Subject ibritumomab tiuxetan Monoclonal antibody 0.4 unknown Intravenous

Indications